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Background: While implications of myocardial fibrosis
on left ventricular (LV) function at rest have been
studied in hypertrophic cardiomyopathy (HCM), the
pathophysiological consequences on dynamic LV
outflow tract (LVOT) gradient have so far not been
investigated in detail.
Objective: To evaluate the influence of myocardial
fibrosis, detected by MRI as late-gadolinium
enhancement (LGE), on LVOT gradient in HCM.
Design: Retrospective database analysis.
Setting: A single Italian cardiomyopathies referral
centre.
Patients: Seventy-six HCM patients with normal
ejection fraction at rest.
Interventions: Patients underwent cardiac MR and
performed bicycle exercise echocardiogram within a
month.
Results: LGE was present in 54 patients (71%),
ranging from 0.2% to 32.4% of LV mass. There
was a weak correlation between the amount of
fibrosis and LVOT gradient variation during
exercise in the overall population (r=−0.243,
p=0.034) and a stronger correlation in patients
with obstructive HCM at rest (r=−0.524, p=0.021).
Patients with an LVOT gradient increase
≥50 mm Hg during exercise had a significantly
lesser extent of fibrosis than those with an
increase <50 mm Hg (0.7% (IQR 0–2.4) vs 3.2%
(IQR 0.2–7.4), p=0.006). The extent of fibrosis
was significantly lower among the highest quartiles
of LVOT gradient increase (p=0.009).
Conclusions: In patients with HCM and normal
ejection fraction at rest, myocardial fibrosis was
associated with a lower increase in LVOT gradient
during exercise, probably due to a lesser degree of
myocardial contractility recruitment. This negative
association was more evident in patients with an
obstructive form at rest.
BACKGROUND
The pathophysiology of hypertrophic cardio-
myopathy (HCM) is the result of a number
of interrelated factors that include impaired
ventricular relaxation, increased myocardial
stiffness, myocardial ischaemia, left ventricu-
lar outflow tract (LVOT) obstruction and
mitral regurgitation.1 2 In recent years MRI
and exercise echocardiography have opened
new possibilities for non-invasive evaluation
of myocardial substrate and LV function in
HCM.3–8 In particular, gadolinium-enhanced
MRI has shown that a high percentage of
patients with HCM has variable degrees of
late-gadolinium enhancement (LGE) which,
in this disease, has been shown to corres-
pond to interstitial fibrosis.6–9 Myocardial
fibrosis in HCM has been shown to be
ARTICLE SUMMARY
Article focus
▪ Exploring influence of myocardial fibrosis
(detected as late-gadolinium enhancement on
cardiac MRI) on left ventricular outflow gradient
during exercise in patients with hypertrophic
cardiomyopathy.
Key messages
▪ Myocardial fibrosis was associated with a lower
increase in left ventricular outflow gradient
during exercise. This negative association was
more evident in patients with an obstructive
form at rest.
Strengths and limitations of this study
▪ This is a first, small, hypothesis-generating study.
▪ Lack of direct haemodynamic measurements.
Biagini E, Lorenzini M, Olivotto I, et al. BMJ Open 2012;2:e001267. doi:10.1136/bmjopen-2012-001267 1
Open Access Research
 group.bmj.com on October 15, 2012 - Published by bmjopen.bmj.comDownloaded from 
associated with an increased incidence of sudden death
risk factors—particularly ventricular arrhythmias—9–11
and an increased risk of HCM-related morbidity and
mortality.12–14 Additionally, myocardial fibrosis influ-
ences LV function at rest negatively.15 16 Not only are
large confluent areas of LGE associated with the end-
stage phase of the disease, but also lesser amounts of
fibrosis seem to determine a reduction in LV systolic
function at rest (albeit within the ‘normal’ ejection frac-
tion (EF) range).15 The relationship between myocardial
fibrosis and LV function during exercise remains unex-
plored. Since LVOT gradient during exercise is mainly
related to the increase in LV contractility, we designed a
hypothesis generating study to explore the relationship
between MRI-assessed myocardial fibrosis and LV
outflow gradient during exercise echocardiography in
HCM patients with normal LV EF.
METHODS
Patients
Ninety-one consecutive outpatients, evaluated at the
S. Orsola-Malpighi University Hospital Bologna, Italy
between January 2009 and November 2010, were consid-
ered for the study. Fifteen patients were excluded due to
coexistent coronary artery disease (n=4), atrial fibrilla-
tion (n=3), previous surgical septal myectomy (n=1), LV
EF <50% at rest (n=2) and general contraindications/
refusal to MRI (n=5). All patients underwent
contrast-enhanced cardiac MRI and bicycle exercise
echocardiogram within a 1-month period. All patients
fulfilled conventional criteria for HCM with LV hyper-
trophy ≥15 mm.17
All patients provided written informed consent for
exercise echocardiography and MR. No specific ethical
approval was required for this study that included only
non-invasive examinations that HCM patients routinely
undergo at our institution.
Exercise echocardiography protocol
Having suspended β-blockers and/or calcium antagonist and
disopiramide for at least five half-lives, patients performed a
symptom-limited bicycle exercise stress test in semisupine
position on an exercise echo-tilting table (stress echo supine
ergometer, Ergoselect 1200 EL, Ergoline GmbH, Bitz,
Germany). The workload was increased by 25 Wevery 2 min.
Blood pressure and 12-lead ECG were recorded every
minute. Echocardiographic images were assessed at baseline
and at peak exercise using a Philips Sonos 5500 Ultrasound
System (Philips Ultrasound, Andover, Massachusetts, USA)
equipped with a harmonic fusion imaging probe (s3) and
off-line cineloop analysis software. All images were recorded
digitally and analysed off-line and each parameter was mea-
sured on an average of three consecutive beats both at rest
and during exercise. LV volumes and EF were calculated
using the Simpson method from the apical four-chamber
and two-chamber view. LV volumes were normalised to the
body surface area. Mitral regurgitation was quantified with
the colour-area method. Continuous wave Doppler was used
to measure LV outflow gradient from the apical four-
chamber view. The early filling (E) and late filling (A) veloci-
ties, as well as the deceleration time of early filling, were
measured from the transmitral flow. Tissue Doppler veloci-
ties were recorded from the medial (septal) and lateral
mitral annulus as previously reported18 and averaged; the
ratio of early mitral diastolic inflow velocity to early diastolic
mitral annular velocity (E/E0) was calculated.
MRI technique
MRI was performed on a 1.5 T scanner (Signa Twin
Speed Excite, General Electric, Milwaukee, Wisconsin,
USA) with surface coils and prospective ECG triggering.
LV end-systolic and end-diastolic diameters as well as
maximal (end-diastolic) wall thickness were traced and
recorded from the short-axis and long-axis views (8 mm
slice thickness, no gap) of the standard ECG-gated
steady state-free precession cine sequence. Image para-
meters were: repetition time 3.5 ms, echo time 1.6 ms,
temporal resolution 40 ms, matrix 224×160, flip angle
45°, bandwidth 125 kHz, views per segment 8–16. LV
volumes, mass and EF were measured from a stack of
sequential 8 mm short axis slices (no gap) from the
atrio-ventricular ring to the apex, through analysis with a
commercially available software (Mass Analysis Plus,
Medis, Leiden, the Netherlands) and were indexed to
body surface in m². LGE images for detection of delayed
hyperenhancement were acquired 10–15 min after intra-
venous administration of Gadopentate dimeglumine
(0.2 mmol/kg) (Magnevist; Schering, Berlin, Germany)
using a breath-hold segmented inversion recovery fast
gradient echo sequence in the short-axis and in long-
axis planes of the LV, with 9 mm slice thickness and no
gap. Image parameters were: repetition time of 5.3 ms,
echo time 1.3 ms, flip angle 20°, matrix 256×160, NEX 2
and field of view 320 mm. Optimal inversion time to
null normal myocardial signal was determined for each
patient and ranged from 220 to 320 ms. After visual
inspection of all short-axis LV slices to identify areas of
completely nulled myocardium (normal myocardium),
the mean signal intensity of normal myocardial tissue
was calculated and a threshold ≥2 SDs exceeding the
mean was used to identify LGE areas. This limit was
deemed acceptable to discriminate LGE from healthy
myocardium without reducing sensibility. LGE areas
were outlined manually and the total volume (expressed
in grams) was quantified using specific software
(ReportCard, GE Medical Systems, Milwaukee,
Wisconsin, USA) and expressed as a percentage of LV
mass. LGE analysis was performed by one experienced
reader (LL, >8 years of MRI experience) and reviewed
by a second reader (RF, >10 years of MRI experience).
Study design and statistical analysis
In order to explore a possible relation between myocar-
dial fibrosis and LV outflow obstruction during exercise
the following analyses were planned:
2 Biagini E, Lorenzini M, Olivotto I, et al. BMJ Open 2012;2:e001267. doi:10.1136/bmjopen-2012-001267
Effects of myocardial fibrosis assessed by MRI
 group.bmj.com on October 15, 2012 - Published by bmjopen.bmj.comDownloaded from 
▸ Linear regression analysis between the extent of fibro-
sis and maximum LVOT gradient during exercise.
▸ Linear regression analysis between the extent of fibro-
sis and changes in LVOT gradient during exercise (in
the overall population and in the patients with an
obstructive form at rest, defined as LV gradient
≥30 mm Hg).
▸ Comparison of fibrosis extent between patients with
maximum gradient ≥ or <50 mm Hg, and between
patients with an increase in exercise gradient ≥ or
<50 mm Hg.
▸ Comparison of fibrosis extent between patients with a
gradient increase above or below the median value in
our population, and among different quartiles of gra-
dient increase.
Categorical variables are expressed as total numbers
and percentages. Continuous variables are expressed as
median values (IQR). Comparison of categorical vari-
ables was performed with the χ2 test and continuous
variables were analysed with the Mann–Whitney U test,
Wilcoxon signed-rank test and Kruskal-Wallis test as
appropriate. A p value of 0.05 was considered to be stat-
istically significant. Regarding echocardiographic mea-
surements, intraobserver variability was assessed in two
different blind evaluations 30 days apart, whereas inter-
observer variability was assessed by two different obser-
vers (GR and EB). Both assessments were made on 15
patients’ sample. Data processing and statistical analyses
Table 1 Baseline clinical, echocardiographic and MR
characteristics
Clinical
Number of patients, n (%) 76
Males, n (%) 51 (67)
Age (years) 48 (41–61)
Family history of HCM, n (%) 34 (45)
Family history of SD, n (%) 10 (13)
NYHA functional class I, n (%) 61 (80)
NYHA functional class II, n (%) 14 (18)
Unexplained syncope, n (%) 12 (16)
NSVT on Holter monitor, n (%) 21 (28)
Echocardiography
LV gradient ≥30 mm Hg at rest, n (%) 20 (26)
Maximum WT (mm) 20 (17–23)
Maximum WT ≥30 mm, n (%) 3 (4)
Left atrium diameter (mm) 43 (39–48)
MRI
LV mass (g/m²) 155 (124–196)
LV mass/end-diastolic volume (g/ml) 1.09 (0.92–1.46)
LGE % of LV mass (%) 2.4 (0–6)
Continuous variables are expressed as median values (IQR).
HCM, hypertrophic cardiomyopathy; LGE, late gadolinium
enhancement; LV, left ventricle; NSVT, non-sustained ventricular
tachycardia; NYHA, New York Heart Association; SD, sudden
death; WT, wall thickness.
Table 2 Echocardiographic data at rest and during exercise
Rest Exercise p Value
Maximum workload (W) 100 (75, 125)
Heart rate (bpm) 73 (66, 84) 128 (112, 142) <0.001
Left ventricle outflow gradient (mm Hg) 11 (7, 31) 27 (16, 98) <0.001
Δ Left ventricle outflow gradient (mm Hg) 14 (8, 46)
Mitral regurgitation jet area (cm²) 1.2 (0.1, 3.1) 3.0 (0.6, 7.1) <0.001
Δ Mitral regurgitation jet area (cm²) 0.6 (0, 3.6)
End-diastolic volume (ml/m²) 35 (28, 45) 29 (20, 40) <0.001
Δ End-diastolic volume (ml/m²) −6 (−12, −2)
End-systolic volume (ml/m²) 8 (5, 12) 5 (3, 7) <0.001
Δ End-systolic volume (ml/m²) −3 (−5, 0)
Stroke volume (ml/m²) 28 (22, 37) 23 (17, 32) <0.001
Δ Stroke volume (ml/m²) −4 (−9, 1)
Ejection fraction (%) 78 (71, 84) 83 (75, 88) <0.001
Δ Ejection fraction (%) 5 (−2, 11)
E wave (cm/s) 71 (59, 89) 97 (83, 121) <0.001
Δ E wave (cm/s) 25 (8, 44)
A wave (cm/s) 73 (60, 91) 104 (84, 125) <0.001
Δ A wave (cm/s) 27 (8, 45)
Deceleration time (ms) 185 (160, 250) Not applicable Not applicable
S wave (cm/s) 7.5 (6.1, 9.0) 9.4 (7.6, 11.9) <0.001
Δ S wave (cm/s) 2.1 (0.7, 3.3)
E0 wave (cm/s) 7.5 (5.9, 9.0) 9.7 (7.4, 13.8) <0.001
Δ E0 wave (cm/s) 3.1 (0.9, 5.0)
A0 wave (cm/s) 8.4 (6.5, 11.1) 11.1 (9.3, 15.5) <0.001
Δ A0 wave (cm/s) 2.5 (0.9, 5.1)
E/E0 9.9 (7.0, 14.2) 9.2 (7.1, 12.8) 0.270
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were performed using the SPSS V.15.0 statistical
program (SPSS Inc, Chicago, Illinois, USA).
RESULTS
LGE was present in 54 patients (71%), involving a per-
centage of LV mass ranging from 0.2% to 32.4%. Fibrosis
consisted of small, diffuse areas in 32 patients (59%) and
was confluent into a smaller number of larger areas in 22
patients (41%). Table 1 reports the clinical, resting echo-
cardiographic and MRI characteristics of the study popu-
lation. Regarding echocardiographic measurements,
mean intraobserver variability for end-diastolic and for
end-systolic volume were 4±1 ml/m² and 3±1 ml/m²,
respectively. Mean interobserver variability for end-
diastolic and for end-systolic volume were 5±1 and
4±1 ml/m², respectively. Mean intraobserver and interob-
server variability of Doppler indexes of LV filling were as
follows: E wave 0.08±2.36 and 1.20±4.30 cm/s; A wave
0.12±1.96 and 0.64±4.54 cm/s.
The variation of echocardiographic characteristics
from rest to exercise is reported in table 2. HCM
patients performed a maximum workload of 100 W
(IQR 75–125) with a median heart rate increase from 73
(IQR 66–84) to 128 (IQR 112–142) bpm. Median LV
outflow gradient increased from 11 (IQR 7–31) to
27 (IQR 16–98) mm Hg on exercise; 15 patients (20%)
without obstruction at rest developed a gradient
≥30 mm Hg on exercise and 18 (24%) had an increase
in outflow gradient ≥50 mm Hg. In 28 patients (37%)
EF did not increase or decreased with exercise.
There was no correlation between the extent of fibro-
sis and maximum LVOT gradient during exercise
(r=−0.197, p=0.087). Considering the variation in LVOT
gradient during exercise, there was a weak correlation
with the extent of fibrosis in the overall population
(r=−0.243, p=0.034) and a stronger correlation in
patients with an obstructive form of the disease at rest
(r=−0.524, p=0.021; figure 1).
Patients with a maximum gradient during exercise
≥50 mm Hg tended to have a lesser amount of fibrosis
than those with a maximum gradient <50 mm Hg; the
difference however did not reach significance (1.1%
(IQR 0–3.9) vs 4.1% (IQR 0.5–8.2), p=0.089). Patients
with an increase in LVOT gradient ≥50 mm Hg had a
significantly lesser extent of fibrosis than those with an
increase <50 mm Hg (0.7% (IQR 0–2.4) vs 3.2% (IQR
0.2–7.4), p=0.006; figure 2). There was no difference in
terms of fibrosis extent between patients with an
increase in LVOT gradient ≥ or < than the median value
(14 mm Hg) (1.7% (IQR 0–4.6) vs 2.8% (IQR 0–7.0),
p=0.330). When dividing the population into quartiles
according to LVOT gradient increase during exercise
the extent of fibrosis was significantly different: in
patients with an increase <8 mm Hg the median value
of fibrosis was 3.4% (IQR 2.2–8.6), in patients with
an increase between 8 and 13 mm Hg was 1.1%
(IQR 0.0–6.6), in patients with an increase between
Figure 1 Linear regression analysis between extent of
fibrosis and changes in left ventricular (LV) outflow tract
gradient during exercise. (A) In the overall population and (B)
in patients with obstructive hypertrophic cardiomyopathy at
rest. Note: the mark indicated by the arrow represents four
patients who showed no late-gadolinium enhancement and an
increase in LV outflow tract gradient during exercise of 50, 50,
51 and 52 mm Hg, respectively.
Figure 2 Fibrosis extent (expressed as median and IQR) in
patients with an increase in exercise gradient < or
≥50 mm Hg.
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14 and 46 mm Hg was 4.4% (IQR 0.7–11.6) and in
patients with an increase ≥ 47 mm Hg median value of
fibrosis was 0.6% (IQR 0.0–2.4, p=0.009).
DISCUSSION
This study shows that myocardial fibrosis (detected as
LGE on MRI) may influence the development of LVOT
gradient during exercise in patients with HCM and
normal EF: patients with higher exercise-induced gradi-
ents show a lesser degree of myocardial fibrosis and
vice versa (figure 3). This negative association is more
evident in patients with an obstructive form at rest.
In recent years, myocardial fibrosis has been emerging
as an important factor in the complex pathophysiology
of HCM. It has been suggested that impairment in colla-
gen turnover could be a component of the disease
phenotype and that it appears as an early manifestation
of sarcomere gene mutations, before the development
of overt LV hypertrophy.19 20 When hypertrophy devel-
ops, increasing amounts of interstitial fibrosis can be
detected non-invasively by gadolinium-enhanced cardiac
MRI.6–8 The exact mechanism leading to fibrosis
remains unknown but it has been hypothesised that the
main triggers for the fibrotic process include molecular
factors at the cellular level (induced by sarcomeric muta-
tions), haemodynamic factors (overall ventricular after-
load resulting from the sum of LV outflow obstruction
and systolic blood pressure), and ischaemia (mainly
related to small intramural coronary vessel disease).8
Myocardial fibrosis in HCM has been associated with the
risk of life-threatening arrhythmias and with a wide spec-
trum of systolic dysfunction, ranging from a mild LV EF
reduction to the end-stage phase.9–14 The present study
confirmed the association between myocardial fibrosis
and contractility, assuming that LV systolic function is
one of the major determinants of the LVOT gradient
increase during effort. The prevalence of myocardial
fibrosis (71%) in our study is comparable with that of
the largest published series;12 14 in most cases, however,
LGE was modest and presented a patchy distribution.
Our results therefore support the concept of a con-
tinuum of haemodynamic effect of myocardial fibrosis
on LV function. Large ‘scar-like’ areas of fibrosis are a
determinant of the end-stage evolution, lesser degrees of
fibrosis are associated with slight EF reduction,14 15
while even lesser degrees of fibrosis, while not influen-
cing EF at rest, seem to result in a lesser contractility
recruitment during exercise, leading to a lower LV
outflow gradient. Notably, the effects of myocardial
fibrosis were particularly evident among patients with LV
outflow gradient already present at rest. Indeed LV con-
tractility is not the only determinant of LV outflow
obstruction; excessive length of the anterior mitral
leaflet, abnormalities in the subvalvular apparatus and
load conditions also play a role.21 In patients with no LV
outflow obstruction at rest (related eg, to the large ana-
tomical size of LVOT and/or a non-redundant mitral
Figure 3 Myocardial fibrosis and changes in left ventricular (LV) outflow tract gradient during exercise. (A) Patient with a large
amount of myocardial fibrosis and modest increase in LV outflow tract gradient. (B) Patient with a limited amount of fibrosis and
relevant increase in LV outflow tract gradient during exercise.
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valve), the increase in contractility could fail to generate
a significant LV gradient increase regardless of the
amount of myocardial fibrosis.
Study limitations
When interpreting our findings one must consider the
low absolute number of patients as well as the fact that
the results derived from the analysis of multiple sub-
groups, even though these were identified with a solid
pathophysiological rationale.
The lack of direct haemodynamic measurement of LV
pressures limits the pathophysiological interpretation of
our data which are essentially based on the behaviour of
LV outflow gradient and indexes of ventricular and myo-
cardial function. Also, our study did not include a
detailed analysis of the behaviour of LV volumes during
exercise and of their correlation with other variables.
Indeed, the small absolute values of LV end-systolic
volume in this disease during exercise (often below the
repeatability threshold) make echocardiography an
unreliable technique for this purpose.
CONCLUSIONS
In patients with HCM and normal EF at rest, myocardial
fibrosis—detected by MRI—is associated with a lower
increase in LVOT gradient during exercise, probably
due to a lesser degree of myocardial contractility recruit-
ment. This negative association is more evident in
patients with an obstructive form at rest.
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